No drug-related treatment-emergent adverse events (TEAEs) were observed in this Phase 1b study, confirming that LBP-EC01 is safe and well tolerated. The clear pharmacodynamic difference between LBP-EC01 and placebo, regardless of MDR status, supports its potential for treating antibiotic-resistant E. coli urinary tract infections. Here, LBP is linked to urinary tract infection.